Rennova Health, Inc. (NASDAQ:RNVA) Files An 8-K Entry into a Material Definitive Agreement

Rennova Health, Inc. (NASDAQ:RNVA) Files An 8-K Entry into a Material Definitive Agreement
Item 1.01. Entry into a Material Definitive Agreement.

Rennova Health, Inc. (the “Company”), on September 27, 2019, issued a promissory note (the “Note”) to a lender in the principal amount of $1,900,000. The Company received proceeds of $1,600,000. The first principal payment of $1,000,000 is due on or before November 8, 2019 and the remaining $900,000 is due on or before December 26, 2019. The Note does not bear interest except upon the occurrence of an Event of Default (as defined in the Note). The Note is unsecured and is guaranteed by Christopher Diamantis, a director of the Company.

The foregoing description of the Note does not purport to be complete and is qualified in its entirety by reference to the form of the Note, which is attached hereto as Exhibit 10.176 and is incorporated by reference herein.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

Exhibit No. Exhibit Description
10.176 Form of Promissory Note, dated September 27, 2019, issued by Rennova Health, Inc. in the principal amount of $1,900,000

––


Rennova Health, Inc. Exhibit
EX-10.176 2 ex10-176.htm   Form of PROMISSORY NOTE   $1,…
To view the full exhibit click here

Story continues below

About Rennova Health, Inc. (NASDAQ:RNVA)

Rennova Health, Inc. (Rennova), formerly CollabRx, Inc., is a provider of diagnostics and supportive software solutions to healthcare providers. The Company operates in three segments: clinical laboratory operations, supportive software solutions, and decision support and informatics operations. The Company is a healthcare enterprise that delivers products and services, including laboratory diagnostics, healthcare technology solutions, and revenue cycle management and intends to provide financial services, to medical providers. Rennova’s principal line of business is clinical laboratory blood and urine testing services. It is also engaged in the provision of urine drug toxicology testing to physicians, clinics and rehabilitation facilities in the United States. Its clinical laboratories include Biohealth Medical Laboratory, Inc.; Alethea Laboratories, Inc.; International Technologies, LLC; EPIC Reference Labs, Inc., and Epinex Diagnostics Laboratories, Inc.

An ad to help with our costs